Statin Therapy for Secondary Prevention in Ischemic Stroke Patients With Cerebral Microbleeds.
Prats-Sanchez L, Camps-Renom P, Nash PS, Wilson D, Ambler G, Best JG, Guasch-Jiménez M, Ramos-Pachón A, Martinez-Domeño A, Lambea-Gil Á, Díaz GE, Guisado-Alonso D, Du H, Al-Shahi Salman R, Jäger HR, Lip GY, Ay H, Jung S, Bornstein NM, Gattringer T, Eppinger S, van Dam-Nolen DH, Koga M, Toyoda K, Fluri F, Phan TG, Srikanth VK, Heo JH, Bae HJ, Kelly PJ, Imaizumi T, Staals J, Köhler S, Yakushiji Y, Orken DN, Smith EE, Wardlaw JM, Chappell FM, Makin SD, Mas JL, Calvet D, Bordet R, Chen CP, Veltkamp R, Kandiah N, Simister RJ, De Leeuw FE, Engelter ST, Peters N, Soo YO, Zietz A, Hendrikse J, Mess WH, Werring DJ, Marti-Fabregas J; Microbleeds International Collaborative Network (MICON).
Prats-Sanchez L, et al.
Neurology. 2024 Apr 9;102(7):e209173. doi: 10.1212/WNL.0000000000209173. Epub 2024 Mar 12.
Neurology. 2024.
PMID: 38471056
Among them, 10,812 received statins at discharge, and 4,668 had 1 or more CMBs. The median follow-up duration was 1.34 years (interquartile range: 0.32-2.44). In patients with CMBs, statin users were compared with nonusers. ...
Among them, 10,812 received statins at discharge, and 4,668 had 1 or more CMBs. The median follow-up duration was 1.34 years (interquartile …